Improved glycemic control with proximal intestinal bypass and weight loss following gastrectomy in non-obese diabetic gastric cancer patients by 源��삎�씪 et al.
Oncotarget104605www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/         Oncotarget, 2017, Vol. 8, (No. 61), pp: 104605-104614
Improved glycemic control with proximal intestinal bypass and 
weight loss following gastrectomy in non-obese diabetic gastric 
cancer patients
Ali Guner1,2, Minah Cho1,3, Taeil Son1,3, Hyoung-Il Kim1,3, Sung Hoon Noh1,3 and 
Woo Jin Hyung1,3
1Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea 
2Department of General Surgery, Karadeniz Technical University College of Medicine, Farabi Hospital, Trabzon, Turkey
3Gastric Cancer Center, Yonsei Cancer Center, Yonsei University Health System, Seoul, Republic of Korea
Correspondence to: Woo Jin Hyung, email: wjhyung@yuhs.ac
Keywords: gastric cancer, gastrectomy, diabetes, proximal intestinal bypass, weight loss
Abbreviations: BMI: Body mass index, DM: Diabetes mellitus, HbA1c: Glycosylated hemoglobin
Received: June 24, 2017    Accepted: September 23, 2017    Published: November 01, 2017
Copyright: Guner et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Purpose: The aim of this study was to assess whether gastrectomy influences 
glycemic control in non-obese diabetic gastric cancer patients and to identify factors 
related to glucose metabolism after gastrectomy.  
Materials and Methods: We retrospectively analyzed changes in glucose 
metabolism in 238 non-obese (body mass index < 30 kg/m2) patients with type 
II diabetes who underwent distal gastrectomy with either gastroduodenostomy 
(n = 91) or gastrojejunostomy (n = 147) for stage I gastric cancer. We collected 
demographics, diabetes-related features, surgery-related features, and changes in 
glucose metabolism during follow-up. The effect of surgery on the course of diabetes 
was evaluated at different time points according to fasting blood glucose levels and 
use of diabetes-related medication.
Results: Preoperatively, the mean body mass index was 24.3 ± 2.3. Weight, 
body mass index and fasting blood glucose of all patients were significantly lower 
compared to preoperative levels at all time points. Weight loss after 6 months and 
the percentage of patients whose weight loss ratio was higher than 10% after one 
year were greater in the gastrojejunostomy group than the gastroduodenostomy 
group. Overall, 88 (37%) patients showed improvement in their diabetes course at 
one month after surgery; 152 (64%) showed improvement after 2 years. Duration 
of diabetes, weight loss, and reconstruction type were associated with improvement 
in diabetes at different time points. At 6 months and thereafter, the percentage of 
patients with an improved diabetes course was highest in the gastrojejunostomy plus 
higher than 10% weight loss group. 
Conclusions: Although weight loss may be associated with adverse effects of 
gastrectomy, postoperative weight loss in an acceptable range is a useful measure of the 
better glycemic control for the group of diabetic patients. Selecting gastrojejunostomy 
during gastrectomy and inducing acceptable weight loss after gastrectomy could be 
beneficial to the non-obese diabetic gastric cancer patients for improved glycemic control. 
INTRODUCTION
Development of diagnostic tools and use of mass 
screening program in East Asia contributed increased early 
detection and resulted in prolonged survival of gastric 
cancer patients [1–3]. Comorbid disease has emerged as 
the leading cause of mortality in gastric cancer patients, 
rather than cancer itself, especially at earlier stages [4–5]. 
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Impairing physico-emotional health and contributing to 
lifestyle limitations, type II diabetes mellitus (DM) is the 
most common comorbidity in gastric cancer patients, with 
an increasing incidence that has already surpassed 15% 
[6]. Although diet, exercise, and pharmacotherapy are the 
primary therapeutic options for treating this progressive 
disease, surgery has recently been recognized as an 
effective treatment modality for managing DM [7]. 
Bariatric surgery was developed as a treatment for 
helping obese individuals achieve weight loss. Subsequent 
studies discovered further benefits for bariatric surgery in 
patients with DM, including improved insulin sensitivity, 
normalization of plasma glucose levels, and rapid declines 
in insulin requirements [8–9]. These observations ushered 
in the use of surgical interventions to manage DM in non-
obese individuals, deemed metabolic surgery. Follow-up 
studies of metabolic surgery in non-obese individuals 
highlighted improvements in glycemic control similar to 
those in obese patients after bariatric surgery [10–11].
Metabolic surgery and gastric cancer surgery 
both result in reduced gastric volume and anatomical 
reconstruction of the stomach. Additionally, studies 
suggest that, like metabolic surgery, gastrectomy also 
elicits favorable changes in glucose metabolism in 
diabetic gastric cancer patients after surgery [12–14]. 
However, these studies included patients with advanced 
stage cancer who received postoperative chemotherapy 
or chemoradiotherapy or patients who underwent total 
gastrectomy, which could potentially affect glycemic 
control. Also, obese patients were included to the 
studies. Thus, the pure impact of gastrectomy on glucose 
metabolism in non-obese diabetic gastric cancer patients 
has not been accurately evaluated.  
Herein, we hypothesized that physiological changes 
in food passage after gastrectomy, together with changes in 
weight, could influence glucose metabolism in non-obese 
diabetic gastric cancer patients. Accordingly, we designed 
this study to assess the effects of changes in food passage 
and weight on glucose metabolism according to glycemic 
profiles and to identify an appropriate procedure for 
surgical reconstruction of the stomach after gastrectomy 
in gastric cancer patients with type II DM. 
RESULTS
Patient characteristics
Of the 238 patients, 179 (75%) were male and 59 
(25%) were female. The mean age was 62.9 ± 8 years. 
The median duration of DM was 8 years (range, 0–36). 
Only 42 patients (17%) had not used any antidiabetic 
medication, while the other 196 patients (83%) were 
prescribed an oral antidiabetic agent, insulin, or both. 
Preoperatively, the median fasting blood glucose level was 
137 mg/dl (range, 61–285 mg/dl) and the median HbA1c 
was 7.2 (range, 4.5–14.8). Preoperative mean weight and 
BMI values were 65.9 ± 8 kg and 24.3 ± 2.3, respectively. 
The median follow-up duration was 58 months (range, 
24–97 months). 
In total, 147 (62%) patients underwent Billroth-I 
gastroduodenostomy; 91 (38%) underwent Billroth-II 
gastrojejunostomy. There were no significant differences 
between the gastroduodenostomy and groups in terms of 
age, gender, BMI, BMI class, diabetes-related features, 
and histopathological features. Mean preoperative 
weights, however, were significantly different between 
the reconstruction groups (64.9 ± 8.3 vs 67.5 ± 7.3). The 
characteristics of all patients and a comparison of the 
patients grouped according to type of reconstruction are 
shown in Table 1.
Changes in weight, BMI, fasting blood glucose, 
and HbA1c 
Changes in weight, BMI, fasting blood glucose, and 
HbA1c were evaluated at 1, 3, 6, 12, and 24 months after 
surgery. Changes in body weight were shown in Figure 
1A. Weight and BMI of all patients were significantly 
lower compared to preoperative levels at all time points. 
Compared to the Billroth I gastroduodenostomy group, 
patients in the Billroth-II gastrojejunostomy group 
showed greater weight loss after 6 months; moreover, the 
percentage of patients in the Billroth-II gastrojejunostomy 
group with a weight loss ratio higher than 10% was 
significantly greater at 12 and 24 months (Figure 1B–1C). 
Fasting blood glucose levels and HbA1c levels of 
both groups during the follow-up period are shown in 
Figure 2A–2B. In paired analysis of all patients regardless 
of the type of reconstruction, fasting blood glucose levels 
showed statistically significant decrease at all time points, 
and HbA1c levels at 3 (median 7.2 (4.5–14.8) vs 6.7 
(5.5–10.3), p = 0.023) and 12 months (median 7.2 (4.5–
14.8) vs 6.8 (6–9), p = 0.033) compared to preoperative 
levels. Patients in the Billroth-II gastrojejunostomy 
group had lower levels of fasting blood glucose at 6 
and 24 months after surgery than those in the Billroth I 
gastroduodenostomy group. There were, however, no 
significant differences in HbA1c levels between the groups 
throughout the follow-up period.
Factors related to improvement in DM
Improvement in glucose metabolism was evaluated 
at 1, 3, 6, 12, and 24 months after surgery. A total of 88 
patients (37%) showed an improved course of glycemic 
profile at one month after surgery. The percentages of 
improved patients were 53% (126 patients), 60% (143 
patients), 71% (169 patients), and 64% (152 patients) at 3, 
6, 12, and 24 months, respectively. 
Univariate analyses were conducted to identify 
factors contributing to changes in the course of glycemic 
profile. During the first and third months, no factor was 
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found to be significantly related with improvement. 
By the 6th month, preoperative fasting blood glucose 
level, duration of DM, weight change, and type of 
reconstruction; by the 12th month, weight change and type 
Table 1: Characteristics of all patients and comparison of groups divided according type of gastric 
reconstruction 
All patients (n:238)
 
Billroth-I 
gastroduodenostomy 
(n: 147)
Billroth-II 
gastrojejunostomy 
(n: 91)
p value
Age (year) 62.9 ± 8 62.9 ± 8.1 63.03 ± 7.9 0.920
Sex 0.086
Male 179 (75%) 105 (71%) 74 (81%)
Female 59 (25%) 42 (29%) 17 (19%)
Duration of diabetes (years) 8 (0–36) 9 (0–36) 7.5 (0–24) 0.075
Weight (kg) 65.9 ± 8 64.9 ± 8.3 67.5 ± 7.3 0.016
Body mass index (kg/m2) 24.3 ± 2.3 24.1 ± 2.3 24.6 ± 2.2 0.085
Body mass index classa 0.210
Normal weight 142 (59%) 93 (63%) 49 (54%)
Overweight 96 (41%) 54 (37%) 42 (46%)
Fasting blood glucose (mg/dL) 137 (61–285) 139 (61–261) 131 (67–285) 0.415
HbA1c (%) 7.2 (4.5–14.8) 7.1 (4.5–14.8) 7.4 (5.7–10.7) 0.607
Antidiabetic treatment 0.805
No treatment 42 (17%) 27 (18%) 15 (17%)
Oral medication 171 (73%) 107 (73%) 64 (70%)
Insulin 12 (5%) 7 (5%) 5 (5%)
Both 13 (5%) 6 (4%) 7 (8%)
Histologyb 0.059
Differentiated 159 (67%) 105 (71%) 54 (59%)
Undifferentiated 79 (33%) 42 (29%) 37 (41%)
T classificationc 0.687
T1 212 (89%) 130 (88%) 82 (90%)
T2 26 (11%) 17 (12%) 9 (10%)
N classificationc 0.488
N0 223 (94%) 139 (95%) 84 (92%)
N1 15 (6%) 8 (5%) 7 (8%)
Pathological stagec 0.928
Stage Ia 197 (83%) 122 (83%) 75 (82%)
Stage Ib 41 (17%) 25 (17%) 16 (18%)
abased on World Health Organization classification
bdifferentiated type includes papillary adenocarcinoma and well or moderately differentiated tubular adenocarcinoma, and 
undifferentiated type includes poorly differentiated adenocarcinoma, signet-ring cell carcinoma, undifferentiated carcinoma, 
or mucinous adenocarcinoma.
cbased on American Joint Committee on Cancer guidelines-7th edition.
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of reconstruction; and by the 24th month, duration of DM, 
weight change, and type of reconstruction were found to be 
significant factors affecting improvement in glycemic profile 
(Table 2). In multivariate analysis, duration of DM was shown 
to be an independent factor for improvement at 24 months; 
weight change was identified as an independent factor at 6, 
12, and 24 months; and type of reconstruction was found to 
be an independent factor at 6, 12, and 24 months (Table 3).
Effects of weight changes and type of 
reconstruction on improvement in DM
The Billroth I gastroduodenostomy and Billroth-II 
gastrojejunostomy groups showed no difference in their 
percentages of patients with improved glycemic profile 
for up to 6 months after surgery. Beginning in the 6th 
month and thereafter, the percentage of patients with 
improvement in glycemic control was statistically higher 
for Billroth-II gastrojejunostomy (Figure 3A). Meanwhile, 
patients experienced a weight loss ratio more than 10% 
showed significantly higher percentage of improvement 
in glycemic control at 12 and 24 months than patients 
experienced a weight loss ratio less than 10% (Figure 3B).
To analyze the combined effect of weight loss and 
type of reconstruction on glycemic profile, we categorized 
patients into four groups according to a weight loss ratio 
of less than or greater than 10%, compared to preoperative 
weight, and whether they underwent gastroduodenostomy 
or gastrojejunostomy for gastric reconstruction. The 
percentages of improved patients in each of the four groups 
are shown in Figure 3C; statistically significant differences 
were noted at 6, 12, and 24 months. In logistic regression 
analysis (reference group is gastroduodenostomy with 
≤ 10% weight loss; Table 4), gastrojejunostomy plus 
≥ 10% weight loss showed the best improvement (OR: 
5.200, 95% CI:1.424–18.991, p = 0.013 at 6 months; OR: 
8.654, 95% CI:1.928–38.848, p = 0.005 at 12 months, 
and OR: 5.371, 95% CI:1.984–14.541, p = 0.001 at 24 
months). Gastrojejunostomy plus ≤ 10% weight loss 
showed the second-best improvement (OR: 2.285, 95% 
CI:1.011–5.166, p = 0.047 at 6 months; OR: 2.510, 95% 
CI:1.030–6.115, p = 0.043) at 12 months and OR: 4.868, 
95% CI:1.986–11.934, p: 0.001 at 24 months).
DISCUSSION
In this study, we discovered that weight loss and 
type of reconstruction are associated with improvements 
in glucose metabolism in non-obese diabetic gastric 
cancer patients after gastrectomy, together with duration 
Figure 1: Changes in body weight (A), weight loss ratio compared to preoperative levels (B) and percentage of patients with a weight 
loss ratio greater than 10% during the follow-up period (C) according to type of reconstruction. Asterisks indicate statistically significant 
differences for percentages between groups.  BMI: Body mass index.
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Table 2: Univariate analysis of variables affecting improvement in glycemic control at different 
time points after surgery
Variables 1st month 3rd month 6th month 12th month 24th month
OR p value OR p value OR p value OR p value OR p value
Age 0.970 0.210 1.016 0.462 1.010 0.581 1.031 0.101 0.988 0.496
Sex
(male* vs female)
0.667 0.815 0.902 0.791 1.165 0.640 1.099 0.780 0.795 0.468
Duration of diabetes 0.970 0.350 0.970 0.261 0.953 0.032 0.978 0.335 0.931 0.002
Preoperative weight 0.985 0.558 0.998 0.914 1.009 0.616 1.009 0.626 1.016 0.348
Preoperative BMI 0.871 0.139 0.984 0.826 1.106 0.111 1.087 0.210 1.032 0.610
Preoperative BMI class 
(normal* vs. overweight)
0.688 0.412 0.729 0.395 1.329 0.341 1.230 0.507 1.184 0.562
Preoperative fasting blood 
glucose
1.001 0.864 0.995 0.186 0.992 0.018 0.994 0.059 0.994 0.073
Preoperative HbA1c 1.091 0.699 0.671 0.057 0.759 0.062 0.822 0.163 0.826 0.166
Preoperative insulin use 
(no* vs. yes)
0.343 0.189 0.831 0.729 1.274 0.602 1.835 0.293 0.753 0.542
Weight change 1.164 0.997 0.939 0.171 0.909 0.004 0.920 0.008 0.907 < 0.001
Method of reconstruction 
(gastroduodenostomy * vs. 
gastrojejunostomy)
0.982 0.978 1.581 0.214 2.739 0.002 4.383 < 0.001 5.100 < 0.001
OR: Odds ratio, BMI: Body mass index, Asterisk indicates the reference variable.
Figure 2: Fasting blood glucose (A) and HbA1c levels (B). Asterisks indicate statistically significant differences between groups.
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of DM. While weight loss resulting from decreased oral 
intake and reduced absorption after surgery can induce 
improvements in DM, duodenal bypass has been shown 
to improve glycemic control in type II DM patients by 
itself [15–17]. In the present study, nonetheless, we 
found that weight loss and duodenal bypass act together 
to improve glucose metabolism after gastrectomy in 
non-obese patients. Interestingly, gastrojejunostomy 
elicited better improvement in glycemic profile than 
gastroduodenostomy by facilitating greater weight loss 
after surgery in non-obese gastric cancer patients.
Among the non-obese patients included in this study, 
weight loss after surgery was found to be an independent 
factor for improvement in DM. For the first 6 months 
after surgery, weight loss amounts were comparable for 
gastroduodenostomy and gastrojejunostomy groups; 
however, in the long term, gastrojejunostomy facilitated 
greater weight loss, as it, unlike gastroduodenostomy, 
involved performing proximal intestinal bypass. 
Similarly, studies comparing gastric bypass or duodenal-
jejunal bypass versus sleeve gastrectomy reported that 
bariatric procedures that bypassed the proximal intestine 
achieved greater weight loss than those that did not 
[18–20]. In accordance with the greater weight loss in 
the gastrojejunostomy group after 6 months, patients 
in this group also showed higher rates of improvement 
in glycemic profile. Meanwhile, however, although 
improvement in DM after gastric resection may be 
explained by weight loss, one study has suggested 
that multiple weight-independent mechanisms affect 
improvements in DM [21].
In addition to weight loss, proximal intestinal 
bypass, as suggested in experimental and human studies, 
was found to be associated with improvement in DM, 
along with a shorter duration of DM [22–27]. Although 
the exact mechanism for DM improvement after duodenal 
bypass is not clear, studies have demonstrated that, 
independent from weight loss, proximal intestinal bypass 
Table 3: Multivariate analysis of variables affecting improvement in glycemic control at different 
time points after surgery
Variables 6th month 12th month 24th month
OR 95% CI p value OR 95% CI p value OR 95% CI p value
Duration of diabetes 0.969 0.921–1.019 0.197 – – – 0.944 0.897-0.993 0.025
Preoperative fasting blood glucose 0.996 0.998–1.003 0.226 – – – – – –
Weight change 0.922 0.860–0.989 0.024 0.931 0.873–0.992 0.028 0.929 0.877–0.983 0.011
Method of reconstruction 0.047 0.008 0.001
Gastroduodenostomy 1 (ref) 1 (ref) 1 (ref)
Gastrojejunostomy 2.128 1.010–4.484 2.894 1.317–6.359 3.781 1.765–8.098
OR: Odds ratio, CI: Confidence interval.
Table 4: Logistic regression analysis of the combined effects of proximal intestinal bypass and 
weight loss on improved glycemic control
6th month 12th month 24th month
Group n OR 95%CI p value n OR 95%CI
p 
value n OR 95%CI
p 
value
Gastroduodenostomy 
and ≤ 10% weight 
loss
114 1 (ref) 114 1 (ref) 110 1 (ref)
Gastroduodenostomy 
and ≥ 10% weight 
loss
33 1.103 0.449–2.709 0.831 33 1.879
0.716–
4.933 0.200 37 2.197
0.922–
5.237 0.076
Gastrojejunostomy 
and ≤ 10% weight 
loss
60 2.285 1.011–5.166 0.047 53 2.510
1.030–
6.115 0.043 49 4.868
1.986–
11.934 0.001
Gastrojejunostomy 
and ≥ 10% weight 
loss
31 5.200 1.424–18.991 0.013 38 8.654
1.928–
38.848 0.005 42 5.371
1.984–
14.541 0.001
n: number of patients, OR: Odds ratio, CI: Confidence interval.
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facilitates improvement in DM via incretins/anti-incretins, 
gut hormones or altered bile acid signaling [28–30]. 
Recently, endoscopically placed medical device which 
mimics the surgical techniques that provide duodenal 
bypass, has been shown effective tool for weight loss 
and metabolic improvement in glucose metabolism 
[31]. Moreover, because Billroth-II gastrojejunostomy 
is common in our practice as a reconstruction method 
after gastrectomy, we evaluated the data of Billroth-
II gastrojejunostomy as the group of duodenal bypass, 
however, we believe Roux-en-Y reconstruction which is 
another reconstruction technique around the world may 
achieve similar outcomes. 
Beyond the metabolic effects of bypassing 
duodenum, the length of bypassed segment of proximal 
intestine is an important point of metabolic surgery and the 
ideal extent of bypassed segment is still under debate [32]. 
In this study, remnant stomach was anastomosed to small 
bowel approximately 20 cm from the ligament of Treitz 
in gastrojejunostomy group patients. This length is shorter 
than the length of biliopancreatic limb, which is used in 
metabolic surgery such as Roux-en-Y gastric bypass or 
duodenal switch. As was shown in previous studies, we 
believe that the increasing of the extent of bypassed segment 
during gastrojejunal anastomosis in gastric cancer surgery 
may result with better glycemic control [33]. However, this 
theory should be evaluated in comparative studies.
Another finding of the present study is shorter 
duration of DM which is typically considered to reflect 
residual beta cell volume and severity of DM, has positive 
effect on amelioration of DM [34]. Although DM duration 
was not associated with improvement in glycemic profile 
in the early period after surgery, it was by year two. This 
finding suggests that diabetic patients with a shorter 
duration of DM and less severe disease might be more 
likely to experience favorable metabolic outcomes after 
surgery. 
Our retrospective and cross-sectional analysis of the 
data should be considered as a limitation of this study. As 
definitions of improvement can vary from study to study, 
there are limitations to analyzing and comparing data 
between studies [12, 35–39]. Because we aimed to assess 
the glucose metabolism according to glycemic profiles in 
different time points, we used the term “improvement” 
rather than the term “remission” which requires at least 
one to five years follow-up period. Nevertheless, since 
several related conditions may alter diabetes status, we 
were cautious in selecting patients for inclusion in the 
study; we exclude individuals who were classified as 
obese or underweight, who received chemotherapy, who 
had advanced cancer, or who underwent total gastrectomy. 
A prospective randomized trial comparing different 
reconstruction procedures for gastric cancer patients with 
DM could potentially show which reconstruction type will 
allow for better improvement and may validate the data 
of our study. Despite the above limitations, our results 
provide the rationale for conducting a well-designed 
prospective study to identify optimal treatment strategies 
for diabetic patients with gastric cancer. Moreover, our 
analysis of non-obese patients may provide the necessary 
evidence with which to expand the application of 
metabolic surgery to non-obese diabetic patients.
In conclusion, our study showed that reconstruction 
type and weight loss affect glycemic control in non-
Figure 3: Percentages of patients with an improved course of diabetes according to reconstruction type (A), weight loss greater than 10% 
(B), and both reconstruction type and 10% weight loss (C). No patient in the gastrojejunostomy plus ≥ 10% weight loss group showed 
improvement during the first month. Asterisks indicate statistically significant differences between groups.
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obese diabetic gastric cancer patients. Patients who 
underwent gastrojejunostomy and were accompanied by 
more weight loss showed the greatest improvement in 
glycemic control. Although weight loss may be associated 
with other adverse effects of gastrectomy, we believe 
that postoperative weight loss in an acceptable range is a 
useful measure of the better glycemic control for the group 
of diabetic patients. Selecting gastrojejunostomy and 
inducing acceptable weight loss after gastrectomy could 
be recommendable in non-obese diabetic gastric cancer 
patients for improved glycemic control. 
MATERIALS AND METHODS
Patient selection
We retrospectively reviewed data stored in a 
prospectively maintained gastric cancer database for 
patients treated at Severance Hospital of Yonsei University 
Health System in Seoul, Korea. We selected type II DM 
patients who underwent distal subtotal gastrectomy 
for stage I gastric cancer without a history of receiving 
chemotherapy. There were 252 patients who met the above 
criteria. Among these, two underweight patients (body 
mass index [BMI] < 18.5) and 12 obese patients (BMI > 
30) were excluded from the analysis. Finally, we analyzed 
238 non-obese, type II DM, stage I gastric cancer patients. 
Data collection
All data on patient demographics, duration of DM, 
reconstruction after resection, fasting blood glucose level, 
glycosylated hemoglobin (HbA1c), body weight, BMI, and 
types of antidiabetic treatment (oral antidiabetic, insulin, 
or both) at the time of surgery and periodically during 
the follow-up period were collected. Patients with fasting 
blood glucose levels higher than 126 mg/dl or plasma 
glucose levels at 2 hour after feeding higher than 200 mg/dl 
were diagnosed as having DM based on criteria set by the 
World Health Organization [40]. We divided the patients 
according to the World Health Organization International 
Classification of BMI: index values between 18.5 and 
25 were defined as normal weight, values below 18.5 as 
underweight, and values between 25 and 30 as overweight. 
To analyze the effect of surgery on weight changes, we 
also divided patients into two groups according to weight 
reductions of less than or greater than 10%.
The effect of surgery on the course of glycemic 
profile was adapted from the American Society for 
Metabolic and Bariatric Surgery recommendations and 
was classified in one of two categories according to fasting 
blood glucose levels and use of diabetes-related medication 
[35–36]. The course of diabetes was deemed to have 
“improved” when patients showed a fasting blood glucose 
level below 126 mg/dL and either used a lower dose of 
antidiabetic medication or converted from insulin to oral 
medication. Patients who experienced no change or an 
aggravation in medication or fasting blood glucose levels 
after surgery were defined as having “not-improved”.  
Gastric reconstruction
Reconstruction after distal gastrectomy was 
performed with either Billroth I gastroduodenostomy 
or Billroth II gastrojejunostomy. While Billroth I 
gastroduodenostomy is relatively simple to perform, 
requiring only one anastomosis and allowing for 
maintenance of physiological intestinal continuity, it can 
only be performed when relatively a small part of the distal 
stomach is removed [41]. If achieving a safe tumor margin 
or acceptable anastomotic tension with gastroduodenostomy 
is not feasible, surgeons perform a gastrojejunostomy for 
reconstruction of the stomach. Billroth-II gastrojejunostomy 
is a gastroenterostomy technique that links the gastric pouch 
to the jejunum at location 15–20 cm distal to the ligament of 
Treitz, bypassing the proximal intestine. 
Statistical analysis
Continuous variables are presented as means ± 
standard deviations for a parametric distribution and 
medians (range) for a nonparametric distribution. The 
chi-square test, Mann-Whitney U test, and Student’s 
t test were used to compare categorical and continuous 
variables as appropriate. The paired analysis was fulfilled 
by paired t test or Wilcoxon signed-rank test. Univariate 
and multivariate analyses of variables were performed 
with logistic regression to identify factors associated with 
improvement in DM. Statistical analysis software (SPSS 
20.0, IBM Corp, Armonk, NY, USA) was used to conduct 
all statistical analyses. All p-values < 0.05 were considered 
statistically significant.
Author contributions
Study conception and design: Guner, Hyung, 
Acquisition of data: Guner, Cho, Son, Hyung, Analysis and 
interpretation of data: Guner, Cho, Kim, Hyung , Drafting 
of manuscript: Guner, Son, Hyung, Critical revision: Guner, 
Cho, Son, Kim, Noh, Hyung.
ACKNOWLEDGMENTS
We would like to thank Anthony Thomas Milliken, 
ELS (Editing Synthase, Seoul, Korea) for his assistance 
with editing the manuscript. We also acknowledge the 
assistance of BioScience Writers, LLC (Houston, TX, USA) 
with copyediting and correction of English language usage. 
CONFLICTS OF INTEREST
The authors have declared no conflicts of interest.
Oncotarget104613www.impactjournals.com/oncotarget
FUNDING
This work was supported by Public-Private 
Investment Technology Development Program  (S2356984). 
REFERENCES
 1. Kim YG, Kong SH, Oh SY, Lee KG, Suh YS, Yang JY, Choi 
J, Kim SG, Kim JS, Kim WH, Lee HJ, Yang HK. Effects 
of screening on gastric cancer management: comparative 
analysis of the results in 2006 and in 2011. J Gastric Cancer. 
2014; 14:129–134.
 2. Nishida T, Tsujii M, Kato M, Hayashi Y, Akasaka T, Iijima 
H, Takehara T. Endoscopic surveillance strategy after 
endoscopic resection for early gastric cancer. World J 
Gastrointest Pathophysiol. 2014; 5:100–106.
 3. Choi KS, Jun JK, Suh M, Park B, Noh DK, Song SH, 
Jung KW, Lee HY, Choi IJ, Park EC. Effect of endoscopy 
screening on stage at gastric cancer diagnosis: results of 
the National Cancer Screening Programme in Korea. Br J 
Cancer. 2015; 112:608–612.
 4. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka 
Y, Ono H, Nagahori Y, Hosoi H, Takahashi M, Kito F, 
Shimada H. Significance of long-term follow-up of early 
gastric cancer. Ann Surg Oncol. 2006; 13:363–369.
 5. Kwon IG, Cho I, Guner A, Kim HI, Noh SH, Hyung WJ. 
Minimally invasive surgery as a treatment option for gastric 
cancer in the elderly: comparison with open surgery for patients 
80 years and older. Surg Endosc. 2015; 29:2321–2330.
 6. Ge Z, Ben Q, Qian J, Wang Y, Li Y. Diabetes mellitus and 
risk of gastric cancer: a systematic review and meta-analysis 
of observational studies. Eur J Gastroenterol Hepatol. 2011; 
23:1127–1135.
 7. Brethauer SA, Aminian A, Romero-Talamás H, Batayyah E, 
Mackey J, Kennedy L, Kashyap SR, Kirwan JP, Rogula T, 
Kroh M, Chand B, Schauer PR. Can diabetes be surgically 
cured? Long-term metabolic effects of bariatric surgery 
in obese patients with type 2 diabetes mellitus. Ann Surg. 
2013; 258:628–636.
 8. Johnson RJ, Johnson BL, Blackhurst DW, Bour ES, 
Cobb WS 4th, Carbonell AM 2nd, Lokey JS, Scott JD. 
Bariatric surgery is associated with a reduced risk of 
mortality in morbidly obese patients with a history of major 
cardiovascular events. Am Surg. 2012; 78:685–692.
 9. Scopinaro N, Adami GF, Papadia FS, Camerini G, Carlini F, 
Briatore L, Andraghetti G, Catalano M, Cordera R.  Effects 
of gastric bypass on type 2 diabetes in patients with BMI 30 
to 35. Obes Surg. 2014; 24:1036–1043.
10. Lee WJ, Chen CY, Chong K, Lee YC, Chen SC, Lee SD. 
Changes in postprandial gut hormones after metabolic 
surgery: a comparison of gastric bypass and sleeve 
gastrectomy. Surg Obes Relat Dis. 2011; 7:683–690.
11. Reis CE, Alvarez-Leite JI, Bressan J, Alfenas RC. Role of 
bariatric-metabolic surgery in the treatment of obese type 
2 diabetes with body mass index < 35 kg/m2: a literature 
review. Diabetes Technol Ther. 2012; 14:365–372.
12. Lee W, Ahn SH, Lee JH, Park DJ, Lee HJ, Kim HH, Yang 
HK. Comparative study of diabetes mellitus resolution 
according to reconstruction type after gastrectomy in gastric 
cancer patients with diabetes mellitus. Obes Surg. 2012; 
22:1238–1243.
13. Kang KC, Shin SH, Lee YJ, Heo YS. Influence of 
gastrectomy for stomach cancer on type 2 diabetes mellitus 
for patients with a body mass index less than 30 kg/m(2). J 
Korean Surg Soc. 2012; 82:347–355.
14. Lanzarini E, Csendes A, Lembach H, Molina J, Gutiérrez 
L, Silva J. Evolution of type 2 diabetes mellitus in non 
morbid obese gastrectomized patients with Roux en-Y 
reconstruction: retrospective study. World J Surg. 2010; 
34:2098–2102.
15. Zervos EE, Agle SC, Warren AJ, Lang CG, Fitzgerald TL, 
Dar M, Rotondo MF, Pories WJ. Amelioration of insulin 
requirement in patients undergoing duodenal bypass for 
reasons other than obesity implicates foregut factors in the 
pathophysiology of type II diabetes. J Am Coll Surg. 2010; 
210:564–572.
16. Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic 
surgery to treat type 2 diabetes: clinical outcomes and 
mechanisms of action. Annu Rev Med. 2010; 61:393–411.
17. Greenway SE, Greenway FL 3rd, Klein S. Effects of obesity 
surgery on non-insulin-dependent diabetes mellitus. Arch 
Surg. 2002; 137:1109–1117.
18. Lee WJ, Chong K, Ser KH, Lee YC, Chen SC, Chen JC, 
Tsai MH, Chuang LM. Gastric bypass vs sleeve gastrectomy 
for type 2 diabetes mellitus: a randomized controlled trial. 
Arch Surg. 2011; 146:143–148.
19.  Garrido-Sanchez L, Murri M, Rivas-Becerra J, Ocaña-
Wilhelmi L, Cohen RV, Garcia-Fuentes E, Tinahones FJ. 
Bypass of the duodenum improves insulin resistance much 
more rapidly than sleeve gastrectomy. Surg Obes Relat Dis. 
2012; 8:145–150. 
20.  Lee WJ, Almulaifi AM, Tsou JJ, Ser KH, Lee YC, Chen SC. 
Duodenal-jejunal bypass with sleeve gastrectomy versus the 
sleeve gastrectomy procedure alone: the role of duodenal 
exclusion. Surg Obes Relat Dis. 2015; 11:765–770.
21. Ting CH, Syu YF, Chen LY, Lee FY, Lee SD, Lee WJ, Chen 
CY. Perspectives on interventional diabetology: Duodenal 
exclusion is promising for human type 2 diabetes mellitus 
remission. Nutrition. 2016; 32:141–145. 
22. Kim JW, Cheong JH, Hyung WJ, Choi SH, Noh SH. 
Outcome after gastrectomy in gastric cancer patients with 
type 2 diabetes. World J Gastroenterol. 2012; 18:49–54.
23. Cummings DE, Overduin J, Foster-Schubert KE. Gastric 
bypass for obesity: mechanisms of weight loss and diabetes 
resolution. J Clin Endocrinol Metab. 2004; 89:2608–2615.
24. Cohen RV, Rubino F, Schiavon C, Cummings DE. Diabetes 
remission without weight loss after duodenal bypass 
surgery. Surg Obes Relat Dis. 2012; 8:e66–68.
Oncotarget104614www.impactjournals.com/oncotarget
25. Patriti A, Facchiano E, Sanna A, Gullà N, Donini A. The 
enteroinsular axis and the recovery from type 2 diabetes 
after bariatric surgery. Obes Surg. 2004; 14:840–848.
26. Pacheco D, de Luis DA, Romero A, González Sagrado 
M, Conde R, Izaola O, Aller R, Delgado A. The effects 
of duodenal-jejunal exclusion on hormonal regulation of 
glucose metabolism in Goto-Kakizaki rats. Am J Surg. 
2007; 194:221–224.
27. de Luis D, Domingo M, Romero A, Gonzalez Sagrado M, 
Pacheco D, Primo D, Conde R. Effects of duodenal-jejunal 
exclusion on beta cell function and hormonal regulation in 
Goto-Kakizaki rats. Am J Surg. 2012; 204:242–247.
28. Kwon Y, Abdemur A, Lo Menzo E, Park S, Szomstein S, 
Rosenthal RJ. The foregut theory as a possible mechanism 
of action for the remission of type 2 diabetes in low body 
mass index patients undergoing subtotal gastrectomy for 
gastric cancer. Surg Obes Relat Dis. 2014; 10:235–242.
29. Li JF, Lai DD, Ni B, Sun KX. Comparison of laparoscopic 
Roux-en-Y gastric bypass with laparoscopic sleeve 
gastrectomy for morbid obesity or type 2 diabetes mellitus: 
a meta-analysis of randomized controlled trials. Can J Surg. 
2013; 56:e158–164.
30.  Batterham RL, Cummings DE. Mechanisms of Diabetes 
Improvement Following Bariatric/Metabolic Surgery. 
Diabetes Care. 2016; 39:893–901.
31.  Vilarrasa N, de Gordejuela AG, Casajoana A, Duran X, 
Toro S, Espinet E, Galvao M, Vendrell J, López-Urdiales 
R, Pérez M, Pujol J. Endobarrier® in Grade I Obese 
Patients with Long-Standing Type 2 Diabetes: Role of 
Gastrointestinal Hormones in Glucose Metabolism. Obes 
Surg. 2017; 27:569–577.
32.  Kim WS, Kim JW, Ahn CW, Choi SH. Resolution of type 
2 diabetes after gastrectomy for gastric cancer with long 
limb Roux-en Y reconstruction: a prospective pilot study. J 
Korean Surg Soc 2013; 84:88–93.
33.  Kim JW, Kim KY, Lee SC, Yang DH, Kim BC. The effect of 
long Roux-en-Y gastrojejunostomy in gastric cancer patients 
with type 2 diabetes and body mass index < 35 kg/m2: 
preliminary results. Ann Surg Treat Res. 2015; 88:215–21.
34. Ferrannini E, Camastra S, Gastaldelli A, Maria Sironi 
A, Natali A, Muscelli E, Mingrone G, Mari A. Beta-cell 
function in obesity: effects of weight loss. Diabetes. 2004; 
53 Suppl 3:S26–33.
35.  Brethauer SA, Kim J, el Chaar M, Papasavas P, Eisenberg 
D, Rogers A, Ballem N, Kligman M, Kothari S; ASMBS 
Clinical Issues Committee. Standardized outcomes 
reporting in metabolic and bariatric surgery.  Surg Obes 
Relat Dis. 2015; 11:489–506.
36.  Aminian A, Brethauer SA, Andalib A, Punchai S, Mackey 
J, Rodriguez J, Rogula T, Kroh M, Schauer PR. Can Sleeve 
Gastrectomy “Cure” Diabetes? Long-term Metabolic 
Effects of Sleeve Gastrectomy in Patients With Type 2 
Diabetes. Ann Surg. 2016; 264:674–81.
37. Scopinaro N, Adami GF, Papadia FS, Camerini G, Carlini 
F, Fried M, Briatore L, D’Alessandro G, Andraghetti G, 
Cordera R. Effects of biliopanceratic diversion on type 2 
diabetes in patients with BMI 25 to 35. Ann Surg. 2011; 
253:699–703. 
38. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, 
Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes 
after bariatric surgery: systematic review and meta-analysis. 
Am J Med. 2009; 122:248–256.
39.  Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, 
Inzucchi SE, McLaughlin S, Phillips GL 2nd, Robertson RP, 
Rubino F, Kahn R, Kirkman MS. How Do We Define Cure 
of Diabetes? Diabetes Care. 2009; 32:2133–5.
40. Alberti KG, Zimmet PZ. Definition, diagnosis and 
classification of diabetes mellitus and its complications. 
Part 1: diagnosis and classification of diabetes mellitus 
provisional report of a WHO consultation. Diabet Med. 
1998; 15:539–553.
41. Xiong JJ, Altaf K, Javed MA, Nunes QM, Huang W, Mai 
G, Tan CL, Mukherjee R, Sutton R, Hu WM, Liu XB. 
Roux-en-Y versus Billroth I reconstruction after distal 
gastrectomy for gastric cancer: a meta-analysis. World J 
Gastroenterol. 2013; 19:1124–1134.
